Hereditary hemochromatosis: Genetic complexity and new diagnostic approaches

Clinical Chemistry

Volumn 52, Issue 6, 2006, Pages 950-968

  Swinkels, Dorine W ^a   Janssen, Mirian C H ^a   Bergmans, Jürgen ^a   Marx, Joannes J M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; FERRITIN; FERROPORTIN 1; GENE PRODUCT; HEPCIDIN; IRON; NEOGENIN; PROTEIN SLC11A2; PROTEIN SLC40A1; TRANSFERRIN RECEPTOR 2; UNCLASSIFIED DRUG;

CLINICAL PATHWAY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; EVIDENCE BASED MEDICINE; GENE; GENE IDENTIFICATION; HAMP GENE; HEMOCHROMATOSIS; HEREDITY; HFE GENE; HJV GENE; HOMEOSTASIS; HUMAN; INTESTINE CELL; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIVER; METABOLIC SYNDROME X; MOLECULAR RECOGNITION; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RELIABILITY; REVIEW;

ANTIMICROBIAL CATIONIC PEPTIDES; CATION TRANSPORT PROTEINS; CLINICAL CHEMISTRY TESTS; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; MEMBRANE PROTEINS;

EID: 33646899011     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.068684     Document Type: Review

References (207)

1. Koppenol WH. The centennial of the Fenton reaction. Free Radic Biol Med 1993;15:645-51.
2. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002;99:3505-16.
3. Marx JJ. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002;15:411-26.
4. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
5. De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T, et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA 2005;102:8955-60.
6. G. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. The presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and downregulated by hepcidin. Blood 2005;106:3979-84.
7. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
8. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, et al. Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family. J Biol Chem 1999;274:20826-32.
9. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-5.
10. McKie AT, Marciani P, Rolfs A, Brennen K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299-309.
11. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001;28:213-4.
12. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-9.
13. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001;98:8780-5.
14. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-10.
15. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-2.
16. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.
17. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117:285-97.
18. Fleming RE, Bacon BR. Orchestration of iron homeostasis. N Engl J Med 2005;352:1741-4.
19. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383-97.
20. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload [Review]. Hematology (Am Soc Hematol Educ Program) 2003;40-61.
21. Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharoen S, Charoenlarp P, et al. The effect of erythroid hyperplasia on iron balance. Blood 1988;71:1124-9.
22. Beutler E. History of iron in medicine. Blood Cells Mol Dis 2002;29:297-308.
23. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochromatosis: demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977;297:1017-21.
24. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991;90:445-9.
25. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists: Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
26. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
27. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
28. Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997;92:784-9.
29. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis, Ann Intern Med 1998;129:925-31.
30. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999;106:619-24.
31. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000;33:485-504.
32. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001;120:718-25.
33. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.
34. McDermott JH, Walsh CH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab 2005;90:2451-5.
35. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-41.
36. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002;16:297-302.
37. Milman N, Pedersen P, Steig T, Byg KE, Graudal N, Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001;80:737-44.
38. Muting D, Kalk JF, Fischer R, Wiewel D. Spontaneous regression of oesophageal varices after long-term conservative treatment. Retrospective study in 20 patients with alcoholic liver cirrhosis, posthepatitic cirrhosis and haemochromatosis with cirrhosis. J Hepatol 1990;10:158-62.
39. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
40. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003;325:332-9.
41. Jacobs EM, Meulendijks CF, Elving L, van der Wilt GJ, Swinkels DW. Impact of the introduction of a guideline on the targeted detection of hereditary haemochromatosis. Neth J Med 2005;63:205-14.
42. Rossi E, Bulsara MK, Olynyk JK, Cullen DJ, Summerville L, Powell LW. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 2001;47:202-8.
43. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-7.
44. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:2448-55.
45. Whitfield JB, Zhu G, Heath AC, Powell LW, Martin NG. Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res 2001;25:1037-45.
46. Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol 2003;30:131-6.
47. Whitfield JB, Cullen LM, Jazwinska EC, Powell LW, Heath AC, Zhu G, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000;66:1246-58.
48. Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002;20:1513-8.
49. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;291:711-7.
50. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422-8.
51. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155-63.
52. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-54.
53. Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol 2005;100:1185-94.
54. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men - the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 2001;25:639-45.
55. Ajioka RS, Jorde LB, Gruen JR, Yu P, Dimitrova D, Barrow J, et al. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. Am J Hum Genet 1997;60:1439-47.
56. Datz C, Haas T, Rinner H, Sandhofer F, Patsch W, Paulweber B. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem 1998;44:2429-32.
57. Beutler E, Felitti V, Gelbart T, Waalen J. Haematological effects of the C282Y HFE mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry. Br J Haematol 2003;120:887-93.
58. Rochette J, Pointon JJ, Fisher CA, Perera G, Arambepola M, Arichchi DS, et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999;64:1056-62.
59. Moalem S, Weinberg ED, Percy ME. Hemochromatosis and the enigma of misplaced iron: implications for infectious disease and survival. Biometals 2004;17:135-9.
60. Deugnier Y, Jouanolle AM, Chaperon J, Moirand R, Pithois C, Meyer JF, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol 2002;118:1170-8.
61. Asberg A, Tretli S, Hveem K, Bjerve KS. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol 2002;37:1212-9.
62. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
63. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004;103:2914-9.
64. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005;143:522-36.
65. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005;143:517-21.
66. Powell LW, Dixon JL, Hewett DG. Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Haematol 2005;18:221-34.
67. Lyon E, Frank EL. Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem 2001;47:1147-56.
68. de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest 2000;30:248-51.
69. de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999;159:1542-8.
70. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000;23:185-92.
71. Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, et al. Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal Biochem 2005;341:241-50.
72. Waalen J, Nordestgaard BG, Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 2005;18:203-20.
73. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2000;2:271-7.
74. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet 1997;349:296-7.
75. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999;93:2502-5.
76. Arya N, Chakrabrati S, Hegele RA, Adams PC. HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors. Blood Cells Mol Dis 1999;25:354-7.
77. Beutler E, Felitti VJ, Ho NJ, Gelbart T. Commentary on HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors by Naveen Arya, Subrata Chakrabrati, Robert A. Hegele, Paul C. Adams. Blood Cells Mol Dis 1999;25:358-60.
78. Le Gac G, Ferec C. The molecular genetics of haemochromatosis. Eur J Hum Genet 2005;13:1172-85.
79. Conrad ME Jr, Crosby WH. Intestinal mucosal mechanisms controlling iron absorption. Blood 1963;22:406-15.
80. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-95.
81. Zhang AS, Davies PS, Carlson HL, Enns CA. Mechanisms of HFE-induced regulation of iron homeostasis: Insights from the W81A HFE mutation. Proc Natl Acad Sci USA 2003;100:9500-5.
82. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 2003;361:669-73.
83. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003;34:97-101.
84. Frazer DM, Anderson GJ. Iron imports: I. Intestinal iron absorption and its regulation. Am J Physiol Gastrointest Liver Physiol 2005;289:G631-G635.
85. Frazer DM, Anderson GJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol Dis 2003;30:288-97.
86. De Almeida SF, Carvalho IF, Cardoso CS, Cordeiro JV, Azevedo JE, Neefjes J, et al. HFE crosstalks with the MHC class I antigen presentation pathway. Blood 2005;106:971-7.
87. Rodriguez MA, Niemela O, Parkkila S. Hepatic and extrahepatic expression of the new iron regulatory protein hemojuvelin. Haematologica 2004;89:1441-5.
88. Lanzara C, Roetto A, Daraio F, Rivard S, Ficarella R, Simard H, et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 2004;103:4317-21.
89. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005;106:2884-9.
90. Zhang AS, West AP Jr, Wyman AE, Bjorkman PJ, Enns CA. Interaction of HJV with neogenin results in iron accumulation in HEK293 cells. J Biol Chem 2005;280:33885-94.
91. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002;99:4596-601.
92. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005;105:1797-802.
93. Viatte L, Nicolas G, Lou DQ, Bennoun M, Lesbordes-Brion JC, Canonne-Hergaux F, et al. Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood 2006;107:2952-8.
94. Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005;2:399-409.
95. Kawabata H, Germain RS, Ikezoe T, Tong X, Green EM, Gombart AF, et al. Regulation of expression of murine transferrin receptor 2. Blood 2001;98:1949-54.
96. Kawabata H, Nakamaki T, Ikonomi P, Smith RD, Germain RS, Koeffler HP. Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood 2001;98:2714-9.
97. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001;97:2555-60.
98. Koyama C, Wakusawa S, Hayashi H, Suzuki R, Yano M, Yoshioka K, et al. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica 2005;90:302-7.
99. Johnson MB, Enns CA. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 2004;104:4287-93.
100. Ganz T. Is TfR2 the iron sensor? Blood 2004;104:3839-40.
101. Fleming RE, Ahmann JR, Migas MC, Waheed A, Koeffler HP, Kawabata H, et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci USA 2002;99:10653-8.
102. Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood 2004;104:4294-9.
103. Wallace DF, Summerville L, Lusby PE, Subramaniam VN. First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 2005;54:980-6.
104. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005;105:1803-6.
105. Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O'Kelly J, et al. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005;105:376-81.
106. Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005;128:470-9.
107. Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004;125:674-8.
108. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005;106:3710-7.
109. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906-12.
110. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;108:619-23.
111. Canonne-Hergaux F, Donovan A, Delaby C, Wang HJ, Gros P. Comparative studies of duodenal and macrophage ferroportin proteins. Am J Physiol Gastrointest Liver Physiol 2005;290:G156-63.
112. Viatte L, Lesbordes-Brion JC, Lou DQ, Bennoun M, Nicolas G, Kahn A, et al. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood 2005;105:4861-4.
113. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1:191-200.
114. Ganz T. Hepcidin - a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171-82.
115. Devalia V, Carter K, Walker AP, Perkins SJ, Worwood M, May A, et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002;100:695-7.
116. Wallace DF, Pedersen P, Dixon JL, Stephenson P, Searle JW, Powell LW, et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 2002;100:692-4.
117. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 2005;105:4096-102.
118. Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003;31:299-304.
119. Barton JC, Acton RT, Rivers CA, Bertoli LF, Gelbart T, West C, et al. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis 2003;31:310-9.
120. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003;31:305-9.
121. McGregor JA, Shayeghi M, Vulpe CD, Anderson GJ, Pietrangelo A, Simpson RJ, et al. Impaired iron transport activity of ferroportin 1 in hereditary iron overload. J Membr Biol 2005;206:3-7.
122. Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005;106:1092-7.
123. Liu XB, Yang F, Haile DJ. Functional consequences of ferroportin 1 mutations. Blood Cells Mol Dis 2005;35:33-46.
124. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004;32:131-8.
125. Fleming RE, Sly WS. Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding. J Clin Invest 2001;:108:521-2.
126. Nemeth E. Ferroportin mutations: a tale of two phenotypes. Blood 2005;105:3763-4.
127. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, et al. Hepcidin in iron overload disorders. Blood 2005;105:4103-5.
128. Zoller H, McFarlane I, Theurl I, Stadlmann S, Nemeth E, Oxley D, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology 2005;42:466-72.
129. Rivard SR, Lanzara C, Grimard D, Carella M, Simard H, Ficarella R, et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the ferroportin 1 gene (SLC11A3) in a large French-Canadian family. Haematologica 2003;88:824-6.
130. Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005;34:157-61.
131. Wallace DF, Clark RM, Harley HA, Subramaniam VN. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. J Hepatol 2004;40:710-3.
132. Njajou OT, de Jong G, Berghuis B, Vaessen N, Snijders PJ, Goossens JP, et al. Dominant hemochromatosis due to N144H mutation of SLC11A3: clinical and biological characteristics. Blood Cells Mol Dis 2002;29:439-43.
133. Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 2003;102:1904-10.
134. Beaumont C, Leneuve P, Devaux I, Scoazec JY, Berthier M, Loiseau MN, et al. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet 1995;11:444-6.
135. Girelli D, Bozzini C, Zecchina G, Tinazzi E, Bosio S, Piperno A, et al. Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. Br J Haematol 2001;115:334-40.
136. Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995;9:267-72.
137. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995;92:2539-43.
138. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78.
139. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003;101:3347-50.
140. Bomford A. Genetics of haemochromatosis. Lancet 2002;360:1673-81.
141. Krawczak M, Cooper DN, Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 2001;69:361-70.
142. Scotet V, Merour MC, Mercier AY, Chanu B, Le Faou T, Raguenes O, et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol 2003;158:129-34.
143. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002;122:281-9.
144. Snover DC. Hepatitis C, iron, and hemochromatosis gene mutations: a meaningful relationship or simple cohabitation? Am J Clin Pathol 2000;113:475-8.
145. Olsson KS, Vaisanen M, Konar J, Bruce A. The effect of withdrawal of food iron fortification in Sweden as studied with phlebotomy in subjects with genetic hemochromatosis. Eur J Clin Nutr 1997;51:782-6.
146. Laine F, Jouannolle AM, Morcet J, Brigand A, Pouchard M, Lafraise B, et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 2005;43:1055-9.
147. Fleming RE, Holden CC, Tomatsu S, Waheed A, Brunt EM, Britton RS, et al. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 2001;98:2707-11.
148. Levy JE, Montross LK, Andrews NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000;105:1209-16.
149. Bensaid M, Fruchon S, Mazeres C, Bahram S, Roth MP, Coppin H. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 2004;126:1400-8.
150. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004;103:2835-40.
151. Le Gac G, Scotet V, Ka C, Gourlaouen I, Bryckaert L, Jacolot S, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004;13:1913-8.
152. Merryweather-Clarke AT, Cadet E, Bomford A, Capron D, Viprakasit V, Miller A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003;12:2241-7.
153. Biasiotto G, Belloli S, Ruggeri G, Zanella I, Gerardi G, Corrado M, et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003;49:1981-8.
154. Biasiotto G, Roetto A, Daraio F, Polotti A, Gerardi GM, Girelli D, et al. Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele. Blood Cells Mol Dis 2004;33:338-43.
155. Lee P, Gelbart T, West C, Halloran C, Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002;29:471-87.
156. Van Vlierberghe H, Langlois M, Delanghe J, Horsmans Y, Michiefsen P, Henrion J, et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001;35:707-11.
157. Tolosano E, Fagoonee S, Garuti C, Valli L, Andrews NC, Altruda F, et al. Haptoglobin modifies the hemochromatosis phenotype in mice. Blood 2005;105:3353-5.
158. Beutler E, Gelbart T, Lee P. Haptoglobin polymorphism and iron homeostasis. Clin Chem 2002;48:2232-5.
159. Sachot S, Moirand R, Jouanolle AM, Mosser J, Fergelot P, Deugnier Y, et al. Low penetrant hemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region. Blood Cells Mol Dis 2001;27:518-29.
160. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood 2000;96:4071-4.
161. Knisely AS, Gelbart T, Beutler E. Molecular characterization of a third case of human atransferrinemia. Blood 2004;104:2607.
162. Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001;69:191-7.
163. Mims MP, Guan Y, Pospisilova D, Priwitzerova M, Indrak K, Ponka P, et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005;105:1337-42.
164. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1. Blood 2005;107:349-54.
165. Camaschella C. DMT1 mutations: mice and humans are not alike. Blood 2005;105:916-7.
166. Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, et al. Identification of an intestinal heme transporter. Cell 2005;122:789-801.
167. Andrews NC. Understanding heme transport. N Engl J Med 2005;353:2508-9.
168. Ohgami RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen J, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 2005;37:1264-9.
169. Lim JE, Jin O, Bennett C, Morgan K, Wang F, Trenor CC, III, et al. A mutation in Sec15I1 causes anemia in hemoglobin deficit (hbd) mice. Nat Genet 2005;37:1270-3.
170. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004;11:251-4.
171. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-50.
172. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005;106:2196-9.
173. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328-33.
174. Gehrke SG, Kulaksiz H, Herrmann T, Riedel HD, Bents K, Veltkamp C, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003;102:371-6.
175. Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine hepcidin assay by mass spectrometry. Blood 2005;106:3268-70.
176. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2005.
177. Adamsky K, Weizer O, Amariglio N, Breda L, Harmelin A, Rivella S, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004;124:123-4.
178. Finch C. Regulators of iron balance in humans. Blood 1994;84:1697-702.
179. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
180. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-6.
181. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005;102:1906-10.
182. Inamura J, Ikuta K, Jimbo J, Shindo M, Sato K, Torimoto Y, et al. Upregulation of hepcidin by interleukin-1β in human hepatoma cell lines. Hepatol Res 2005;33:198-205.
183. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
184. Weiss G, Gordeuk V, Hershko C, eds. Anemia of Chronic Disease. Boca Raton, FL: CRC Press Taylor & Francis Group, 2005:752pp.
185. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573-8.
186. Kotisaari S, Romppanen J, Penttila I, Punnonen K. The Advia 120 red blood cells and reticulocyte indices are useful in diagnosis of iron-deficiency anemia. Eur J Haematol 2002;68:150-6.
187. Franck S, Linssen J, Messinger M, Thomas L. Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis. Clin Chem 2004;50:1240-2.
188. Akesson A, Bjellerup P, Vahter M. Evaluation of kits for measurement of the soluble transferrin receptor. Scand J Clin Lab Invest 1999;59:77-81.
189. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood 2003;101:3359-64.
190. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, et al. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735-43.
191. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004;42:387-9.
192. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels and hepatic function. Blood 2005;106:746-8.
193. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-13.
194. Shan Y, Lambrecht RW, Bonkovsky HL. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin Infect Dis 2005;40:834-41.
195. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004;363:357-62.
196. Pietrangelo A. Non-invasive assessment of hepatic iron overload: are we finally there? J Hepatol 2005;42:153-4.
197. St Pierre TG, Clark PR, Chua-Anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
198. Bonkovsky HL, Rubin RB, Cable EE, Davidoff A, Rijcken TH, Stark DD. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999;212:227-34.
199. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005;100:837-41.
200. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776-81.
201. Moura E, Noordermeer MA, Verhoeven N, Verheul AF, Marx JJ. Iron release from human monocytes after erythrophagocytosis in vitro: an investigation in normal subjects and hereditary hemochromatosis patients. Blood 1998;92:2511-9.
202. Wallace DF, Summerville L, Lusby PE, Subramaniam VN. Prohepcidin localizes to the Golgi compartment and secretory pathway in hepatocytes. J Hepatol 2005;43:720-8.
203. Wallace DF, Jones MD, Pedersen P, Rivas L, Sly LI, Subramaniam VN. Purification and partial characterisation of recombinant human hepcidin. Biochimie 2006;88:31-7.
204. Rockwell NC, Krysan DJ, Komiyama T, Fuller RS. Precursor processing by kex2/furin proteases. Chem Rev 2002;102:4525-48.
205. Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilisation. Proc Natl Acad Sci USA 1997;94:10919-24.
206. Knisely AS. Neonatal hemochromatosis. Adv Pediatr 1992;39:383-403.
207. Lambrecht RW, Bonkovsky HL. Hemochromatosis and porphyria. Semin Gastrointest Dis 2002;13:109-19.